Drug intelligence / Profile preview

VERU-944

Development stage: Preclinical
Lead developer: Veru
Administration: Oral

Overview

VERU-944 is an investigational drug that was part of the pipeline of products acquired by Veru (formerly The Female Health Company) from Aspen Park Pharmaceuticals. It is being developed for various cancers.

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on VERU-944.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VERU-944.

Explore the full profile